Bristol Myers Target Price and Analyst Consensus

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

The current analyst and expert consensus on Bristol Myers is Buy with 4 hold recommendations. The current projected Bristol Myers target price consensus is 65.78 with 9 analyst opinions. One of the most common ways Bristol Myers Squibb analysts use to provide buy or sell recommendation to the public are conference calls analysis and financial statements evaluations. Some experts can also talk to Bristol Myers vendors, executivess, and/or customers. Bristol Myers recommendation module provides expert sentiment on the projected Bristol Myers Squibb target price to derive its highest and lowest estimates based on target price standard deviation of 9.718. Continue to Macroaxis Advice on Bristol Myers to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.

Search Analyst Recommendations

Profit Margin is likely to grow to 0.14 in 2020, whereas Gross Profit is likely to drop slightly above 17.7 B in 2020. Bristol Myers Book Value per Share is fairly stable at the moment as compared to the past year. Bristol Myers reported Book Value per Share of 31.67 in 2019. Price to Book Value is likely to grow to 2.08 in 2020, whereas Tangible Assets Book Value per Share are likely to drop 23.10 in 2020.

Bristol Myers Target Price Consensus

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bristol target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bristol target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Number of Opinions12
Lowered Outlook0
Raized Outlook0
Most Bristol analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Bristol stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Bristol Myers Squibb, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice   Exposure   Valuation

Bristol Myers Target Price Projection

Current Price

Bristol Myers Market Quote on 13th of July 2020

Low Price57.16Odds
High Price58.09Odds


Target Price

Analyst Consensus On Target Price

Low Estimate50.0Odds
High Estimate80.0Odds
Number of Analysts9
Standard Deviation9.718


Bristol Myers Analysit Ratings

Average Consensus

About Bristol Myers Target Price Projections

Bristol Myers's target price is an analyst's projection of its future price. Price targets can be assigned to all types of securities, from complex investment products to stocks such as Bristol Myers Squibb and even bonds. If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now. Generally, the target price of Bristol depends on its intrinsic valuation, beta (i.e. risk over market), and overall volatility. Most analysts publish their price targets in research reports on specific companies, along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Bristol Myers Squibb
 2017 2018 2019 2020 (projected)
Long Term Debt to Equity0.590.40.840.91
Interest Coverage18.4327.979.019.25
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page